3rd Annual Guggenheim Healthcare Innovation Conference
Logotype for Olema Oncology Inc

Olema Oncology (OLMA) 3rd Annual Guggenheim Healthcare Innovation Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Olema Oncology Inc

3rd Annual Guggenheim Healthcare Innovation Conference summary

10 Nov, 2026

Palazestrant trials

  • OPERA-01 compares palazestrant with fulvestrant or exemestane after CDK4/6 inhibitor plus AI progression; top-line results expected in Q1 2027.

  • Post-CDK4/6 market estimated at $5B annually: ESR1-mutant patients represent ~$2B and wild type ~$3B; phase II median PFS was 7.3 months and 5.5 months, respectively.

  • OPERA-02 is a 1,000-patient first-line trial of ribociclib plus palazestrant versus ribociclib plus letrozole; enrollment is robust.

  • OPERA-02 could add patients if SERENA-4 shows a stronger-than-historical control arm; potential resizing may affect the readout forecast.

  • First-line opportunity estimated at $10B+; palazestrant plus ribociclib showed median PFS over one year post-CDK4/6 plus AI in phase II, without enhanced toxicity or dose modifications.

Clinical rationale and upcoming data

  • Palazestrant is a complete estrogen receptor antagonist and degrader; high exposure and sustained receptor blockade are cited as rationale for activity in ESR1 wild-type disease.

  • OPERA-01 analyzes ESR1-mutant and wild-type subsets independently; either subset meeting its hazard-ratio and critical P-value criteria could make the trial positive.

  • Q1 2027 disclosure is expected to report trial outcomes in both ESR1 subsets; fuller details are planned for a subsequent medical meeting.

  • PERSEVERA missed its hazard-ratio threshold by a few hundredths but showed a favorable trend and ~5-month PFS difference; its treatment-free-interval criterion is not used in OPERA-02.

  • San Antonio presentations will include palazestrant combinations with everolimus and atirmociclib; everolimus data will include ESR1-mutant and wild-type results.

KAT6 inhibitor program

  • OP-3136 showed single-agent activity in metastatic ER-positive, HER2-negative breast cancer and castration-resistant prostate cancer; dose escalation reached 80 mg daily, with MTD still undetermined.

  • Fulvestrant combination dose-escalation data, including early response and tolerability, are planned for San Antonio; palazestrant combination data are expected mid-2027.

  • NUBEQA combination enrollment in prostate cancer is expected to begin in the coming months; earliest shareable data are expected later in 2027.

  • Narrower KAT selectivity is hypothesized to reduce cytopenias; dysgeusia is a side effect seen across this class of agents.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Olema Oncology